Absci (ABSI) and Owkin said Friday that they formed a partnership to develop therapeutic candidates addressing novel targets in immuno-oncology and other indications such as inflammation.
The partnership will use Owkin's predictive AI models to optimize target selection and validate therapeutic hypotheses, while Absci's generative AI Drug Creation platform will design therapeutic candidates against the selected novel targets, according to a joint statement.
Financial terms were not disclosed.
Shares of Absci were down more than 9% in recent trading.
Price: 2.92, Change: -0.30, Percent Change: -9.32
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。